Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 261

Sort by

Sort Order Select

Journal Articles

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL

Lorena Fontan, Rebecca Goldstein, Gabriella Casalena, Matthew Durant, Matthew R. Teater, Jimmy Wilson, Jude Phillip, Min Xia, Shivem Shah, Ilkay Us, Himaly Shinglot, Ankur Singh, Giorgio Inghirami, Ari Melnick

Blood (2021) 137 (6): 788–800.

https://doi.org/10.1182/blood.2019004713

Published: 2021

Includes: Supplemental data

Journal Articles

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Tomoyasu Jo, Momoko Nishikori, Yasunori Kogure, Hiroshi Arima, Katsuhiro Sasaki, Yoshiteru Sasaki, Tomoko Nakagawa, Fumie Iwai, Shuji Momose, Aki Shiraishi, Hiroshi Kiyonari, Noritaka Kagaya, Tetsuo Onuki, Kazuo Shin-ya, Minoru Yoshida, Keisuke Kataoka, Seishi Ogawa, Kazuhiro Iwai, Akifumi Takaori-Kondo

Blood (2020) 136 (6): 684–697.

https://doi.org/10.1182/blood.2019002654

Published: 2020

Includes: Supplemental data

Journal Articles

A role for NFAT signaling in ABC-DLBCL

Jagan R. Muppidi

Blood (2020) 135 (2): 81.

https://doi.org/10.1182/blood.2019004199

Published: 2020

Journal Articles

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

Giorgia Chiodin, Joel Allen, Philip J Rock, Enrica Antonia Martino, MD, Beatriz Valle Argos, PhD, Graham Packham, PhD, Patrick Duriez, PhD, Teunis Geijtenbeek, PhD, Carl Figdor, PhD, Richard Burack, MD PhD, Max Crispin, PhD, Freda K Stevenson, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2019) 134 (Supplement_1): 1505.

https://doi.org/10.1182/blood-2019-127159

Published: 2019

Journal Articles

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

David M. Kurtz, MD PhD, Joanne Soo, MD, Stefan Alig, MD, Lyron Co Ting Keh, Charles Macaulay, Michael C. Jin, BS, Florian Scherer, MD, Emily G. Hamilton, BS, Chih Long Liu, PhD, Binbin Chen, PhD, Alexander F. M. Craig, MPhil, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 552.

https://doi.org/10.1182/blood-2019-131267

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Blood (2019) 134 (Supplement_1): 2765.

https://doi.org/10.1182/blood-2019-124444

Published: 2019

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

Xiaolei Wei, PhD, Jialin Song, Yongqiang Wei, PhD, Hong Zeng, Weimin Huang, PhD, Jingxia Zheng, Ru Feng, MD

Blood (2019) 134 (Supplement_1): 5237.

https://doi.org/10.1182/blood-2019-127705

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Xiangnan Jiang, MD, Wanhui Yan, Yifeng Sun, Qinghua Xu, Xiaoyan Zhou, MD, Junning Cao, Xiaonan Hong, Xiaoqiu Li

Blood (2019) 134 (Supplement_1): 5337.

https://doi.org/10.1182/blood-2019-126629

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, MD, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, MD PhD, Arianna Di Napoli, Tamar Tadmor, MD, Antonino Maiorana, Valentina Donati, MD, Sara Galimberti, MD PhD, Stefano Sacchi, MD

Blood (2019) 134 (Supplement_1): 1617.

https://doi.org/10.1182/blood-2019-125689

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

Xin Xu

Blood (2019) 134 (Supplement_1): 5046.

https://doi.org/10.1182/blood-2019-126763

Published: 2019

Journal Articles

MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

Blood (2019) 134 (Supplement_1): 5092.

https://doi.org/10.1182/blood-2019-128492

Published: 2019

Journal Articles

Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B-Cell Lymphoma - a Single Center Experience

Ashok K Vaid, MDDM, Suman S Karanth, MD DNB, Aseem Khurana, MBBS ,M.Ed, Nitin Sood, MDFRCPath,MRCP, Ashok Sen, MD, Gautam Dheeraj, MD, Bhuvan Chugh, DNB, Saurabh Mishra, MD DNB

Blood (2019) 134 (Supplement_1): 5350.

https://doi.org/10.1182/blood-2019-126414

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Blood (2019) 134 (Supplement_1): 3805.

https://doi.org/10.1182/blood-2019-129262

Published: 2019

NARROW

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

A role for NFAT signaling in ABC-DLBCL

Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Subtyping Diffuse Large B-Cell Lymphoma with Cell-of-Origin Using 32-Gene Expression Assay in Formalin-Fixed Paraffin-Embedded Tissue

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B-Cell Lymphoma - a Single Center Experience

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only